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Abstract
Genetic instability plays an important role in ovarian carcinogenesis. Genetic instability is
one of the characteristics shared by most human cancers and seems to exist (at various
levels) at all stages of the disease, from precancerous lesions to advanced cancer. It is pos‐
sible that this instability is one of the first trigger events, which would facilitate the subse‐
quent establishment of all the other cancer hallmarks. Telomere shortening appears to
take place in most human preinvasive epithelial lesions: short telomeres are found in up
to 88% of early precancerous conditions of the bladder, cervix, colon, esophagus, or pros‐
tate. However, little is known about ovarian carcinogenesis and telomere shortening. Re‐
cent evidence has shown that the fallopian tube may be the origin of ovarian cancer. A
new tubal carcinogenic sequence has been described with precancerous lesions that could
metastasize to the ovary and result in invasive ovarian cancer. In this review, we will de‐
scribe the degree of telomere shortening and genomic instability (estimated by the ex‐
pression of DNA damage response proteins, such as H2AX, Chk2, ATM, 53BP1, p53, and
TRF2, and by array comparative genomic hybridization) in early preinvasive stages of
ovarian cancer (serous tubal intraepithelial carcinoma (STIC)), ovarian high-grade serous
carcinoma, and benign controls. Given that STICs have the shortest telomeres, they could
be in a telomere crisis phase preceding genomic stabilization due to telomerase activation
(see appended diagram). Concordant results were obtained in immunohistochemical and
molecular studies. The expression of all DNA damage proteins increased from benign fal‐
lopian tubes to STICs suggesting an early activation of the DNA damage response (DDR)
pathways in STICs and indicating that genomic instability may occur early in the precan‐
cerous lesions of high-grade serous ovarian cancer (HGSC). In this chapter, we propose to
review current knowledge about the function of human telomeres and telomerase and
their relevance in genomic instability in cancer and to focus on specific results for ovarian
cancer.
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1. Introduction
1. 1. Telomeres, telomerases, and p53 interaction
Genomic instability is probably one of the first phases in carcinogenesis and would thus
facilitate the accumulation of multiple mutations. This instability was first described in
connection with the discovery of microsatellite instability with the hereditary non-polyposis
colon cancer (HNPCC) or Lynch syndrome for example. In most cancers, there is another form
of genomic instability, that is, the chromosomal instability (CIN), which we will describe in
this review [1]. At molecular level, this instability could result in chromosome rearrangements
(number and structure), duplication or segregation anomalies during mitosis, along with DNA
repair system dysfunction [1–4]. The CIN may be explained by the mutator hypothesis in
hereditary cancers (germline mutations in DNA repair genes as TP53 or BRCA genes for
instance, beginning in the precancerous lesions) and by the oncogene-induced DNA replica‐
tion stress in sporadic (non-hereditary) cancers [1]. Because CIN precedes TP53 and DNA
repair genes mutations in sporadic cancer, genomic instability would be the result of activated
oncogenes or antioncogenes (growth signaling pathways...) [1]. However, in both cases
(sporadic and genetic cancers), CIN may be due also to telomere erosion and is likely linked
to multifactorial molecular events.
Telomere dysfunction has been described to be one of the initial phases in genomic instability.
Telomeres are found at the tips of the chromosomes and consist of a large number of hexamer
(TTAGGG)n repeats capped with the multiprotein shelterin complex. Their main function is
to protect chromosomal ends from fusion and nucleotidic degradation, which ensures
chromosomal stability. Telomeres are regularly shortened during cell division due to incom‐
plete replication of telomeric DNA. Excessive shortening (a “telomere crisis”) activates DNA
repair at telomeres leading to CIN and finally cell death. In tumors, telomeres are usually
shortened, which makes the cell unstable, but the activation of telomerase (telomere elongation
complex generally found only in stem, progenitor, and tumor cells and not in normal somatic
cells) maintains the telomere length at a certain level, enabling the survival of these cells [2–
4]. These unstable cells can then continue to proliferate and this results in cancer. The interac‐
tion between telomeres and p53 would thus represent one of the trigger events in carcinogen‐
esis [5]. In physiological terms, telomere shortening represents a real “genotoxic stress”
resulting in activation of the DNA damage signaling pathway (and consequently p53 tumor
suppressor protein), finally leading to apoptosis or cycle arrest. When p53 is inactivated by
mutations, as is the case in ovarian high-grade serous carcinoma, the telomere dysfunction is
neither repaired nor signaled, resulting in genomic instability with the accompanying
chromosome aberrations, which are a prelude to cancer [2–6].
DNA double-strand breaks can be the result of telomere dysfunction and are one of the most
critical DNA alterations at the origin of genomic instability. One of the first response mecha‐
nisms aimed at repairing these breaks is activation of the DNA damage checkpoints. These
checkpoints represent the transition state between two cell phases that may be inhibited by
genotoxic lesions. There is then a slowing or complete halt in the progression from one phase
to the next (checkpoint G1/S or G2/M) or during replication (checkpoint intra-S) [7].
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The phosphorylation of ATM (a member of the phosphoinositide 3-kinase or PI3 kinase) occurs
first. Then ATM phosphorylates Chk2 p53, H2AX, and 53BP1. Chk2 also phosphorylates p53
(Figure 1) [8–12]. Histone H2AX phosphorylated on residue serine 139, also called γH2AX, is
a marker for cellular DNA double-strand breaks. Phosphorylation of H2AX results in the
condensation of chromatin each side of the break, which makes γH2AX detectable at nuclear
level by immunohistochemistry.
Figure 1. Relationship between telomeres and the DNA damage response pathway. DNA double-strand breaks may
be the result of telomere dysfunction with activation of the DNA damage checkpoints. The apical kinase ATM is first
activated. Then ATM activates the DNA damage mediators, H2AX and 53BP1. ATM also phosphorylates the down‐
stream kinase Chk2, which phosphorylates p53. ATM may directly activate the effector p53. In non-cancerous situa‐
tion, this pathway leads to checkpoint arrest, cellular senescence, or apoptosis. In cancerous situation, this cascade may
activate tumor proliferation to invasive carcinoma. On the left side, you can see the serous carcinogenic sequence from
benign fallopian tube (no p53 mutation) to serous tubal intraepithelial carcinoma (the precancerous lesion with p53
signature) and after that ovarian cancer (with also TP 53 mutation) [15, 17].
Strong expression of γH2AX was detected in most precancerous lesions and was considered
to represent an antitumor function. Experimental studies have shown that H2AX-deficient
mice were at greater risk of immunodeficiency, infertility, and were also more sensitive to
ionizing radiation, all of which can be explained by increased chromosomal instability related
to reduced capability of the DNA repair systems. When these mice were also p53 deficient
(knock-out), there was an increased risk of tumors [13, 14].
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As it has been demonstrated that telomere shortening occurs early during carcinogenesis
(being found in 89% of preinvasive lesions of the bladder, cervix, colon, and also the esopha‐
gus) [5], we investigated genetic instability in precancerous ovarian lesions, which has been
described very recently.
2. Ovarian cancer: A model for greater insight into genetic instability
This review concerns high-grade serous ovarian cancer (HGSC) characterized by a higher
genomic instability (see below) and very frequent TP53 gene mutations. Germline mutations
in breast cancer susceptibility 1 (BRCA 1) or BRCA 2 may lead to hereditary HGSC, whereas
90% of HGSC are sporadic (no BRCA mutations but frequent BRCA inactivation or modulation
with promoter hypermethylation, loss of heterozygosity in over 50% of cases) [15].
Four hundred and eighty-nine HGSC were recently studied by the Cancer Genome Atlas
Research Network [16]. TP53 mutations were present in 96% of cases followed by mutations
in NB1, BRCA1, BCA2, RB1, and CDK12 genes. Homologous recombination (and the DNA
damage signaling pathway) is defective in about half of the cancers analyzed [16]. Taken
together, all these findings can explain why ovarian cancer may be a relevant model to explore
genetic instability.
Recent histopathologic and molecular studies enabled to describe a model of tumorogenesis
comprising two pathways [15]:
• Type I tumors: These are low-grade tumors for which the pathogenesis would consist of a
sequence of cystadenomas/adenofibromas, then borderline tumors and finally progression
towards cancer. A lesional continuum has indeed been found, that is, molecular mutations
that are common to benign, borderline, and invasive lesions (BRAF and KRAS mutations in
over 60% of cases, less frequently mutated PTEN (20%–46%) and β-catenin (≈30%). Note
also the recent discovery of ARID1A gene mutations in endometriosis and cancers associ‐
ated with endometriosis (clear cell and endometrioid cancers) [17].
• Type II tumors: These are high-grade tumors from the outset. At the molecular level, TP53
gene mutations are found in 50%–80% of cases. These tumors show high genomic instability
and are essentially represented by HGSC. This histologic subtype is the most frequent and
consequently has been the subject of many studies, and a tubal carcinogenic sequence has
been identified [15].
True occult intraepithelial cancerous lesions of the tube (serous tubal intraepithelial carcino‐
ma (STIC)) have been reported unusually often in the distal portion of tubes obtained after
prophylactic  adnexectomy  for  BRCA  mutation,  prompting  systematic  and  meticulous
examination of these tubes [18–23]. They show epithelial stratification, nuclear atypicalities with
an increase in the nucleocytoplasmic ratio, loss of nuclear polarity, nuclear pleiomorphism, and
loss of ciliated cells. Immunohistochemical analysis may reveal intense and diffuse expres‐
sion of p53 (the p53 signature) and a high proliferative index (Ki67> 40%). There could be a high
level of genetic instability, as demonstrated by the high positive level of γH2AX [15, 16, 18–23].
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In other words, high-grade ovarian serous carcinoma could originate in the fallopian tube, and
all these findings encouraged us to study STIC lesions and genomic instability.
We started by assessing the telomere length in 12 STICs, 36 non-cancerous controls, and 43
high-grade serous cancers [24, 25]. Laser microdissection of paraffin-embedded samples was
used in all cases. A DNA extraction was followed by purification step. Telomere length was
measured by real-time quantitative polymerase chain reaction (PCR) according to Cawthon’s
method [26].
STICs had the shortest telomeres (p=0.0008). Telomeres of invasive cancer were shorter than
those in benign controls but longer than telomeres found in STICs. A significant correlation
was also found between overexpression of p53 and H2AX proteins and shortened telomeres
in STICs (p<10−7) [24]. Kuhn et al [27] used fluorescence in situ hybridization technique to
analyze telomere length of a series of 22 STICs in comparison with non-cancerous controls and
high-grade cancers: 82% of STICs had the shortest telomeres, followed by the cancers. The
controls had the longest telomeres. These findings suggest that STIC lesions are the most
unstable genetically and are likely to represent one of the first steps in tubo-ovarian carcino‐
genesis.
We also studied these STICs by array comparative genomic hybridization (aCGH) using
oligonucleotide microarrays (Agilent 180 K) [24].
The size of rearrangements in STICs was high, with an average of 2363.37 Kb (488–8161).
We found common gains at chromosomes 19q (6/12, 50%), 16p (5/12, 41.6%), 12q (5/12, 41.6%),
10q (5/12, 41.6%), 11p (4/12, 33.3%), 4p (3/12, 25%), and 8q (3/12, 25%), and common losses at
chromosomes 3q (6/12, 50%), 2q (5/12, 41.6%), 11q (4/12, 33.3%), 6p (4/12, 33.3%), 22q (4/12,
33.3%), 18q (3/12, 25%), 19p (3/12, 25%), 20p (3/12, 25%), and 2 p (2/12, 16.6%) [24]. These early
rearrangements could be key steps in these first phases of carcinogenesis, and the correspond‐
ing candidate genes could be involved directly in the tumor triggering process, meaning that
they could represent diagnostic and/or treatment targets. More studies are required.
Finally, in another study, we investigated the level of DDR activation in STICs by immuno‐
histochemistry (pATM, pChk2, γH2AX, 53BP1, and TRF2) [28]. We constructed a tissue
microarray, including 21 benign fallopian tubes, 21 STICs, and 30 HGSCs. We demonstrated
that the expression of all DDR proteins increased from benign fallopian tubes to STICs.
Analysis of staining variance within cases showed that 53BP1, γH2AX, pATM, pCHK2, and
TRF2 expressions were significantly higher in STICs than in HGSC [28].
Taken together, all our results have shown evidence of genomic instability in the precancerous
lesions known as STICs. Of note among the frequent chromosomal breakpoints in STICs, more
than half occurred at terminal bands, which is characteristic for a telomere crisis with the
occurrence of telomere fusions, leading to chromosomal aberrations.
It could also be interesting to study human telomerase reverse transcriptase (hTERT) expres‐
sion, which is a determinant for telomerase activity, and also the telomere architecture proteins
(shelterin complex proteins TRF1, TRF2, and POT1) in STICs and HGSC [29–33]. TRF1 and
TRF2 proteins are involved in negative regulation of telomere lengthening and interact with
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telomerase [29, 30]. POT1 appears to play a dual antagonist role, depending on cell conditions,
acting as positive or negative regulator of telomere length depending on telomerase [6, 34]. In
our study [28], the level of expression of TRF2 was increased in STICs in comparison with
HGSC (p=0.012). It has been shown that TRF2 may shorten telomeres without telomerase
inactivation [12]. TRF2 is also phosphorylated by ATM to enable DNA damage repair in
response to DNA damage [12].
Telomerase would probably be activated after telomere shortening at the invasive stage and
would thus counteract further telomere shortening: stabilization of telomere length at this
stage would moreover represent an advantage in terms of tumor proliferation and escaping
apoptosis [3].
Wang et al [35] investigated the relationship between telomere length and telomerase activity
in 15 ovarian cancers. The authors found telomeric dysfunction in 9/15 (60%) and telomerase
activation in 11/15 (73.3%) ovarian cancers. However, they did not study precancerous lesions.
Other authors demonstrated that telomerase activity was higher in ovarian carcinoma than in
borderline tumors (considered as premalignant tumors) and normal ovary [36–38]. This was
confirmed in cell cultures [39]. However, telomerase activity in STICs has not yet been studied.
3. Conclusion
Telomere shortening has been proven to be one of the potential precursors of ovarian cancer
indicative of genomic instability. This could lead to significant preventive strategies such as
prophylactic salpingectomy in patients with a genetic risk of ovarian cancer in order to avoid
the malignant transformation of benign fallopian tube into STIC [40].
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